Similarly, among metastatic IBC patients, the HR+HER2− subtype is not associated with an indolent course and indeed has similar or worse overall survival (OS) compared to triple positive or HR-HER2 + patients [9]. This evidence concerns the gene ERBB2 and inflammatory breast carcinoma.